obesity drug news today glp-1 2025 sep 30 Outlook for in 2025: more than a transition year GLP-1 therapies are changing obesity

Current evidence suggests that while delayed gastric emptying is a genuine pharmacologic effect, the absolute risk of serious aspiration-related complications may be lower than initially feared, particularly among stable patients without gastrointestinal symptoms

In fact, a 2024 Centers for Disease Control study noted an impressive 26.5% GLP-1 adoption rate in American adults diagnosed with diabetes

As this group expands, their shopping and behavioral changes could present marketplace risks for food and beverage manufacturers

[DOI] [PubMed] [Google Scholar] 116.Buse J.B., Bain S.C., Mann J.F.E., Nauck M.A., Nissen S.E., Pocock S

J Clin Invest 101(6):13341341

States have the option of imposing either stricter or looser requirements on these polices